Mapping from disease-specific measures to utility: An analysis of the relationships between the inflammatory bowel disease questionnaire and Crohn's disease activity index in Crohn's disease and measures of utility

Value in Health

Volumn 10, Issue 3, 2007, Pages 214-220

  Buxton, Martin J ^a   Lacey, Loretto A ^b   Feagan, Brian G ^c   Niecko, Timothy ^d   Miller, David W ^e   Townsend, Raymond J ^e  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b Lacey Solutions Ltd   (Ireland)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d Niecko Health Economics   (United States)

^e ELAN PHARMACEUTICALS   (United States)

Author keywords

CDAI; Crohn's disease; EQ 5D; IBDQ; SF 6D; Utility

Indexed keywords

ALGORITHM; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; ENTERITIS; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; OBSERVATION; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; REGRESSION ANALYSIS; SCORING SYSTEM; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; VALIDATION STUDY; VALIDITY; VARIANCE;

EID: 34249026625     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00171.x     Document Type: Article

References (18)

1. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990 16 : 199 208.
2. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 21 : 271 92.
3. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single attribute utility functions for the health utilities index mark 3 system. Med Care 2002 40 : 113 28.
4. Sengupta N, Nichol MB, Wu J, Globe D. Mapping the SF-12 to the HUI3 and VAS in a managed care population. Med Care 2004 42 : 927 37.
5. Lundberg I, Johannesson M, Isacson D, et al. The relationship between health state utilities and the SF-12 in a general population. Med Decis Making 1999 12 : 128 40.
6. Longworth L, Buxton M, Sculpher M, Smith DH. Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ 2005 6 : 347 53.
7. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 44.
8. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989 96 : 804 10.
9. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health related quality of life. Am J Gastroenterol 2004 18 : 465 6.
10. Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and the SF-6D across seven patient groups. Health Econ 2004 13 : 873 84.
11. Konig H-H, Ulshofer A, Gregor M, et al. Validation of the Euroqol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002 14 : 1205 15.
12. Sandborn WJ, Colombel JF, Enns R, et al. for the International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) and the Evaluation of Natalizumab As Continuous Therapy (ENACT-2) Trial Groups. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005 353 : 1912 25.
13. Gregor JC, McDonal JW, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997 3 : 265 76.
14. Brooks R, with the EuroQol Group. EuroQol: the current state of play. Health Pol 1996 37 : 53 72.
15. Dolan P. Modeling valuations for EuroQol Health States. Med Care 1997 11 : 1095 108.
16. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473 81.
17. Cheung WY, Garratt AM, Russell IT, Williams JG. The UK IBDQ-a British version of the inflammatory bowel disease questionnaire, development and validation. J Clin Epidemiol 2000 53 : 297 306.
18. Szende A, Oppe M, Devlin N (eds). EQ-5D value sets: Inventory, comparative review and user guide. Dordrecht, The Netherlands : Springer, 2007.